8-K: Vaxart Reports Positive 12-Month Safety Data for Oral COVID-19 Vaccine

Vaxart announced topline 12-month safety data from its Phase 2b trial, showing no vaccine-related serious adverse events in its oral COVID-19 vaccine candidate compared to an mRNA comparator.

Summary

• Vaxart, Inc. released topline 12-month safety data from the sentinel safety cohort of its Phase 2b clinical trial for its oral pill COVID-19 vaccine candidate.
• The trial involved approximately 400 participants, with 201 receiving Vaxart's oral vaccine and 199 receiving an approved mRNA vaccine.
• No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events (AEs) were reported in either the oral vaccine group or the mRNA vaccine group.
• Common AEs for the oral vaccine included malaise/fatigue (20.9%), headache (18.9%), and anorexia (10.0%).
• Common AEs for the mRNA vaccine included injection site pain (60.3%), injection site tenderness (40.2%), malaise/fatigue (35.2%), myalgia/muscle pain (33.2%), and headache (28.6%).
• Symptomatic COVID cases were reported in 33 participants in the oral vaccine arm and 30 in the mRNA arm.
• Asymptomatic COVID cases were reported in 12 participants in each arm.
• The safety cohort was not powered to determine comparative efficacy.
• Topline data from the complete study, including a main cohort of approximately 5,000 participants, are anticipated in 2027.
• The main cohort is designed to provide a statistical comparison of safety and relative efficacy.
• Funding for the trial is supported by Project NextGen, an initiative by BARDA and NIAID, with Vaxart's project award valued at up to $344.8 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the strong safety profile demonstrated in the sentinel cohort, which is a critical hurdle for any vaccine candidate. However, the lack of efficacy data and the long wait for full study results temper the enthusiasm.

Positives

• No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events were reported in the 400-participant sentinel safety cohort for either Vaxart's oral vaccine or the mRNA comparator.
• The safety profile observed in this cohort is consistent with previously observed safety profiles of Vaxart's oral vaccine constructs.
• The oral pill vaccine offers potential advantages such as storage and shipping without refrigeration and elimination of needle-stick injury risk.

Negatives

• The safety cohort was not powered to determine comparative efficacy between the oral vaccine and the mRNA comparator.
• The number of symptomatic COVID cases was similar between the oral vaccine arm (33 participants) and the mRNA vaccine arm (30 participants).
• The number of asymptomatic COVID cases was also similar between the oral vaccine arm (12 participants) and the mRNA vaccine arm (12 participants).

Risks

• The ability to meet anticipated clinical endpoints, retain participants, collect follow-up data, and generate sufficient evaluable cases and events.
• The possibility of unfavorable new clinical data and further analyses of existing clinical data that may differ from or not confirm topline data.
• The risk that clinical trial data may not support conclusions regarding safety, tolerability, immunogenicity, efficacy, or relative efficacy.
• Uncertainty regarding regulatory authorities' satisfaction with the study design, comparator, endpoints, statistical assumptions, strain selection, safety database, and efficacy analyses.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect commercial potential.
• The possibility that Vaxart's product candidates may not be approved, authorized, or licensed by regulatory authorities.
• Results from the Phase 2b trial may not be sufficient to support regulatory submissions, interactions, approval, authorization, licensure, or commercialization.
• Risks related to government funding, including whether amounts will be available, released, reimbursed, or sufficient, and potential modifications, reductions, delays, suspensions, or terminations of the award.
• Potential manufacturing, supply, storage, shipment, stability, quality control, or quality assurance issues and delays.
• Difficulties in production scaling, including production costs and yields, quality control, stability, shortages of qualified personnel or key raw materials, and compliance with regulations.
• Vaxart's ability to obtain sufficient capital to fund operations on acceptable terms.
• Impact of changes in government public-health, procurement, and funding priorities.
• Changes in COVID-19 incidence, circulating variants, vaccination recommendations, and market demand.
• Competition from approved and investigational COVID-19 vaccines and other vaccine technologies.

Future Outlook

Topline data from the complete Phase 2b study, comprising the sentinel safety cohort and approximately 5,000 participants in the main cohort, are anticipated in 2027. The main cohort is designed and powered to support the planned statistical comparison of safety and relative efficacy outcomes. Further analyses of the sentinel safety cohort are ongoing.

Management Comments

• "These topline safety data are encouraging and are consistent with the safety profile observed to date in other studies of our oral pill vaccine constructs," said James Cummings, MD, Chief Medical Officer at Vaxart.
• "We know that safety and tolerability are critical factors in successful vaccine development, and we are pleased with how our investigational vaccine performed in this cohort."
• "These first cohort topline data are an important advancement for our COVID-19 program and for our oral pill vaccine platform overall," said Steven Lo, Chief Executive Officer at Vaxart.
• "This study adds to the body of evidence supporting the safety profile of our vaccine constructs as we look to demonstrate the potential of our proprietary oral delivery technology."
• "We believe more insights into our oral COVID program are important and will be further analyzing this cohort as we eagerly await the readout from the main cohort of this trial, which is expected to provide more robust information on safety and efficacy."

Industry Context

StockSavvy.ai notes that Vaxart's announcement positions its oral pill COVID-19 vaccine candidate as a potentially differentiated offering in a market increasingly focused on convenience and alternative delivery methods beyond intramuscular injections. The positive safety data, while preliminary for efficacy, align with the broader industry trend of exploring diverse vaccine platforms to address evolving public health needs and potential future pandemics.

Stakeholder Impact

• Shareholders: Positive sentiment may be boosted by the favorable safety data, but the long timeline for efficacy results and potential market competition could temper significant price movements.
• Employees: Continued progress in clinical trials can foster morale and job security.
• Regulatory Bodies: The data will be reviewed for potential approval pathways, with safety being a primary concern.
• Healthcare Providers: The development of an oral vaccine could offer a more convenient option for administration, potentially increasing vaccination rates if efficacy is proven.

Next Steps

• Further analysis of the sentinel safety cohort data.
• Awaiting topline data from the complete Phase 2b study, including the main cohort, which is anticipated in 2027.
• Continue development of oral pill vaccines for coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for HPV.

Key Dates

Recommendation

The filing presents positive safety data for Vaxart's oral COVID-19 vaccine candidate, which is a crucial step. However, the absence of efficacy data in this announcement and the anticipated 2027 readout for the full study results mean that significant investment decisions cannot be made solely on this information. The market will await comparative efficacy and further safety data. Therefore, a 'hold' recommendation is appropriate, pending more comprehensive results.

Keywords

Vaxart, COVID-19 vaccine, oral vaccine, Phase 2b trial, safety data, clinical trial, mRNA vaccine, BARDA, NIAID, Project NextGen, biotechnology, vaccine development